5. Segment information

Management has identified one single operating segment, related to the discovery, development and commercialization of small-molecule pharmaceutical products.

Information about products, services and major customers

External income of the Group for the years ended December 31, 2025, 2024 and 2023 is derived from the business of discovery, development and commercialization of pharmaceutical products. Income was earned from rendering of research services to a pharmaceutical company and grants earned.

Information about geographical areas

External income is exclusively recorded in the Swiss operating company.

Analysis of revenue from contract with customer and other income by nature is detailed as follows:

​

​

Analysis of revenue from contract with customer and other income by major counterparties is detailed as follows:

​

​

For more detail, refer to note 15, “Revenue from contract with customer” and note 16 “Other Income”.

The geographical allocation of long-lived assets is detailed as follows:

​

​

The geographical analysis of operating costs is as follows:

​

​

There was capital expenditure of CHF 1,273 in 2024 and CHF 6,842 in 2023. In 2025, the capital expenditure was nil.